SynthesisIntegrative cancer therapies
Efficacy of Melatonin in Alleviating Radiotherapy-Induced Fatigue, Anxiety, and Depression in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Synthesis in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundBreast cancer (BRCA) remains the most diagnosed malignancy among women globally and is predominantly managed through multimodal therapy. Radiotherapy, an essential component of BRCA management, often causes fatigue, anxiety, and depression that compromise the quality of life (QoL) of patients. Melatonin, an endogenous hormone with antioxidant, anti-inflammatory, and circadian rhythm-modulating properties, has shown potential for preventing radiotherapy-associated toxicities. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of melatonin in alleviating radiotherapy-induced fatigue, anxiety, and depression among breast cancer patients.MethodsFollowing PRISMA guidelines (PROSPERO: CRD420251144916), a comprehensive search was conducted across PubMed, Scopus, Cochrane Library, Embase, and Google Scholar up to August 2025. RCTSs comparing melatonin with placebo in adult female patients with non-metastatic breast cancer undergoing adjuvant radiotherapy were included. The Cochrane RoB-2 tool was employed for quality assessment. Pooled standardized mean differences (SMDs) and mean differences (MDs) were calculated using a random-effects model in RevMan 5.4 software.ResultsFive RCTs encompassing 561 patients were analyzed. Melatonin significantly reduced fatigue severity (SMD = -0.43; 95% CI -0.65 to -0.20; p = 0.0002) and improved cognitive functioning (MD = 1.16; 95% CI 0.95 to 1.36; p < 0.00001) and global health status (MD = 2.47; 95% CI 2.07 to 2.87; p < 0.00001). No significant effects were observed for emotional, social, or physical functioning, nor for gastrointestinal, pain, or sleep-related domains.ConclusionBased on limited number of studies, melatonin supplementation appears to be a safe, well-tolerated, and low-cost adjunct to radiotherapy, capable of improving fatigue, cognitive performance, and overall QoL in breast cancer patients. However, small sample sizes and heterogeneous dosing regimens require further large-scale RCTs to establish optimal dosing and long-term efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.